Finepoint Capital LP Amicus Therapeutics, Inc. Transaction History

Finepoint Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$11.78 - $13.86 $1.92 Million - $2.26 Million	163,250 Added 12.31%	1,489,025 $18.1 Million
Q2 2023 Aug 11, 2023	SELL	$10.72 - $13.3 $1.44 Million - $1.79 Million	-134,400 Reduced 9.2%	1,325,775 $16.7 Million
Q1 2023 May 12, 2023	BUY	$10.91 - $13.54 $345,847 - $429,218	31,700 Added 2.22%	1,460,175 $16.2 Million
Q4 2022 Feb 13, 2023	SELL	$9.89 - $12.7 $2.57 Million - $3.3 Million	-259,925 Reduced 15.39%	1,428,475 $17.4 Million
Q3 2022 Nov 10, 2022	SELL	$9.82 - $12.75 $3.17 Million - $4.11 Million	-322,500 Reduced 16.04%	1,688,400 $17.6 Million
Q2 2022 Aug 12, 2022	BUY	$6.23 - $11.12 $12.5 Million - $22.4 Million	2,010,900 New	2,010,900 $21.6 Million

312

311M

467K

515K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.58B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

Stay updated on Finepoint Capital LP with notifications on news.